A Phase 1/2 interventional study of Autologous bone marrow stem cells in Osteoarthritis, sponsored by International Stemcell Services Limited. Status unknown at 1 site in India. Open to participants aged 30 Years to 70 Years. Per ClinicalTrials.gov, last updated 2011-06-09.
Sponsored by International Stemcell Services Limited · Phase 1/2, Interventional, and Treatment
Osteoarthritis is a leading cause of chronic disability in elderly and the risk of disability attributed to osteoarthritis is as great as or greater than due to any other medical condition in that age group. Several cross sectional studies have demonstrated an age related increase in the prevalence of osteoarthritis of knee(5). Results of survey are similar with most surgeons reporting 50+ years age group being commonest at initial presentation and that the incidence increases with advancing age. Interestingly some surgeons have noticed earlier occurrence of osteoarthritis in 40+ years age group and one has to be careful to screen for secondary causes in this younger age group patients.
While pain relief is the primary treatment goal of osteoarthritis medications, localized inflammation may also be relieved by using certain drugs. Managing osteoarthritis pain can involve medications, natural remedies, exercise, weight loss, joint protection, mobility aids, assisted devices and more.
Stem cell therapy, using cells extracted from the same patient or suitable alternative human sources, targets diseases which are either incurable or with no complete or effective treatment available in the traditional healthcare system. Since this therapy is based on the concept of regenerating damaged cells in the injured or disease-affected areas of the body, it is called regenerative medicine
Autologous stem cells provide an attractive option for osteoarthritis patients and their clinicians.
In our present study we want to evaluate the safety and efficacy of autologous bone marrow derived stem cells in treatment of Osteoarthritis for therapeutic chondrogenesis through delivery of stem cells into the knee joint space in ten Indian patients.
4,398 studies on the registry are indexed under Osteoarthritis; 582 are open to participants now.
This study's planned enrollment of 10 is below the median of 70 across 3,440 interventional studies indexed under Osteoarthritis.
Browse Osteoarthritis studies →International Stemcell Services Limited is the lead sponsor of 2 studies on the registry; none are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
Other: Autologous bone marrow stem cells
Stem cells isolated from the patient's own bone marrow.
Pain as measured by the The Western Ontario and McMaster Universities Arthritis Index (WOMAC) Pain Score
Time frame: Baseline, 3 months, 6 months, 1 year
Number of Participants with Adverse Events as a Measure of Safety and Tolerability
Time frame: 1 year
Changes in the MRI knee with cartilage mapping and clinical improvement
Time frame: Baseline, 6 months, 1 year
This study is status unknown, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
International Stemcell Services Limited